PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations

Published:2019-04-05 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Dong Qiuju,Yu Pengfei,Ye Liang,Zhang Jianzhao,Wang Hongbo,Zou Fangxia,Tian Jingwei,Kurihara Hiroshi

Funder

Natural Science Foundation of Shandong Province

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-42245-3.pdf

Reference32 articles.

1. Monroy-Estrada, H. I., Chirino, Y. I., Soria-Mercado, I. E. & Sánchez-Rodríguez, J. Toxins from the Caribbean sea anemone Bunodeopsis globulifera increase cisplatin-induced cytotoxicity of lung adenocarcinoma cells. J. Venom. Anim. Toxins Incl. Trop. Dis. 19, 12, https://doi.org/10.1186/1678-9199-19-12 (2013).

2. Aisner, D. L. & Marshall, C. B. Molecular pathology of non-small cell lung cancer: a practical guide. Am. J. Clin. Pathol. 138, 332–346, https://doi.org/10.1309/ajcpfr12wjkceezz (2012).

3. Kazaz, S. N. & Öztop, İ. Treatment after first-generation epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Turk. Thorac. J. 18, 66–71, https://doi.org/10.5152/turkthoracj.2017.16042 (2017).

4. Galli, G. et al. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: a case series and literature review. Lung Cancer 115, 135–142, https://doi.org/10.1016/j.lungcan.2017.12.002 (2018).

5. O’Kane, G. M. et al. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer 109, 137–144, https://doi.org/10.1016/j.lungcan.2017.04.016 (2017).

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents;Current Medicinal Chemistry;2024-06-10

2. Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists;iScience;2024-02

3. ERCC6 plays a promoting role in the progression of non-small cell lung cancer;Biochemistry and Cell Biology;2023-06-01

4. Role of Tyrosine Kinases and their Inhibitors in Cancer Therapy: A Comprehensive Review;Current Medicinal Chemistry;2023-04

5. Dual kinase inhibitor for EGFR mutants and ErbB2 limit breast cancer;Biochemical and Biophysical Research Communications;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3